Albemarle (ALB) Stock Could Be 48% Undervalued As Cash Flow Leads The Case
Albemarle stock has delivered a strong 64.7% return over the past year, yet its valuation signals are pulling in different directions, with an intrinsic value estimate from a Discounted Cash Flow (DCF) model suggesting upside while market multiples point to a richer price and the broader checks lean cautious.
- Over the last 12 months the share price return of 64.7% puts Albemarle firmly in recovery territory, which can leave less room for error if expectations prove too optimistic.
- The key support for the valuation is the market’s focus on Albemarle’s future cash flow potential. The main risk is that cash generation or margins fall short of what is currently implied in the share price.
- Albemarle scores 2 out of 6 on the broader valuation checks. This suggests the stock does not screen as a clear bargain overall even if certain models look attractive here.
The issue now is whether Albemarle’s recent share price recovery is already pricing in the intrinsic value suggested by the DCF work, or if there is still a reasonable margin of safety left for new investors.
Is Albemarle Still Cheap on Cash Flow?
The Discounted Cash Flow (DCF) approach estimates what Albemarle is worth today based on the cash it is expected to generate in the future. For Albemarle, the model uses last twelve month free cash flow of about $619 million and assumes cash flows that are growing over time, consistent with the 2 Stage Free Cash Flow to Equity setup.
On these assumptions, the DCF points to an estimated intrinsic value of about $251 per share. Compared with the current share price, this implies the stock trades at a 47.7% discount to that intrinsic value. In other words, the cash flow outlook built into the model suggests the market price is still some way below what those projected cash streams support.
On this DCF view, Albemarle stock screens as undervalued relative to its estimated intrinsic value.
Our Discounted Cash Flow (DCF) analysis suggests Albemarle is undervalued by 47.7%. Track this in your watchlist or portfolio, or discover 52 more high quality undervalued stocks.
Has Albemarle Run Too Far on Sales?
P/S is a useful cross check for Albemarle because revenue tends to be less volatile than earnings and can give a cleaner read on how the market values its sales base. Albemarle currently trades on a P/S of about 2.6x, which is close to the peer group average of 2.5x but well above the broader Chemicals industry average of 1.2x. That indicates the market already assigns Albemarle a premium to the typical sector player.
The fair P/S ratio implied by the model is about 1.9x. This is lower than where Albemarle stock trades today, so the current multiple sits above what the company’s profile would suggest as a more neutral level. The gap is not extreme, yet it does indicate that investors are paying a higher multiple for Albemarle’s revenue compared with this tailored benchmark.
On the P/S multiple, Albemarle stock appears expensive relative to the level suggested by its fundamentals and sector benchmarks.
See what the numbers say about this price — find out in our valuation breakdown.
The Albemarle Narrative: What Would Justify Today's Price?
Simply Wall St Narratives for Albemarle sit between the DCF and P/S results and explain what those signals really assume about Albemarle's future. Narratives lay out the growth, margin and earnings paths that would need to occur for the stock to be worth materially more or less than today's price. Where a single ratio or model gives one figure, these narratives spell out the future that figure depends on so you can track how reality compares over time on Simply Wall St's Community page.
Community views on Albemarle sit far apart, with one camp leaning into tightening supply and contracts while the other focuses on technology and policy risks.
Bull case: 30% undervalued
"With ~50% of sales volumes locked under long-term agreements with major Western OEM and battery customers, Albemarle benefits from enhanced revenue stability and reduced cyclicality..."
Read the full Bull Case to see why Albemarle could be undervalued
Bear case: 5% overvalued
"The long-term outlook for lithium demand faces structural headwinds from significant advances in alternative battery chemistries and energy storage technologies that do not require lithium..."
Read the full Bear Case to see why Albemarle could be overvalued
Do you think there's more to the story for Albemarle? Head over to our Community to see what others are saying!
The Bottom Line
Albemarle looks cheap on a Discounted Cash Flow (DCF) view, yet screens as overvalued on sales multiples, so the signals do not line up cleanly. The low broader valuation score suggests treating the intrinsic value estimate as only one piece of the puzzle, rather than a clear green light. The gap between the two methods comes down to how much weight you put on future cash flow potential versus what the market is already paying for each dollar of revenue. The real swing factor from here is whether Albemarle can deliver the cash generation implied in the intrinsic value without eroding margins.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com